Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has officially initiated its A-share listing process on the Shanghai Stock Exchange's Sci-Tech Innovation Board, aiming to raise approximately 9.52 billion yuan through the issuance of 57 million shares, which will account for 13.67% of the total share capital post-issuance [1] Group 1: Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - The company has developed the first domestically produced 60MHz high-definition IVUS product and the first domestically approved FFR measurement system in China [1] Group 2: Product Development and Market Position - As of September 30, 2025, Beixin Life has launched 11 products and has 6 products under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [2] - The FFR system captured a 30.6% market share in China shortly after its launch in 2020, with over 70% of its domestic usage coming from tertiary hospitals [2] Group 3: Financial Performance and Projections - Beixin Life's revenue is projected to grow significantly, with expected revenues of 520 million to 560 million yuan in 2025, representing a year-on-year growth of 64.24% to 76.88% [3] - The company anticipates a substantial increase in net profit, with estimates ranging from 78 million to 88 million yuan, reflecting a year-on-year growth of 278.91% to 301.85% [3] Group 4: Strategic Initiatives and Future Outlook - The funds raised from the IPO will be primarily allocated to the construction of an industrialization base for interventional medical devices, R&D projects, and to supplement working capital [3] - The company aims to enhance its capital structure, reduce debt risk, and improve its resilience against market fluctuations, while also expanding production capacity and strengthening R&D capabilities [3]
北芯生命发布招股意向书 募资加码介入医疗器械研发与产业化
Zheng Quan Shi Bao Wang·2026-01-16 01:52